{"id":"ckd-330","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available regarding the specific molecular mechanism of CKD-330. As a phase 3 candidate from Chong Kun Dang, a South Korean pharmaceutical company, the drug is in late-stage clinical development, but detailed mechanistic data has not been widely published in accessible databases.","oneSentence":"CKD-330 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not publicly disclosed in standard references.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:10.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04627207","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-11","conditions":"Cardiovascular Diseases","enrollment":51},{"nctId":"NCT04611932","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-11-11","conditions":"Cardiovascular Disease","enrollment":51},{"nctId":"NCT04478097","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-07-14","conditions":"Cardiovascular Disease","enrollment":51},{"nctId":"NCT04019743","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-07-28","conditions":"Hypertension, Dyslipidemias","enrollment":24},{"nctId":"NCT03583905","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-04-04","conditions":"Hypertensive Patients With Dyslipidemia","enrollment":154},{"nctId":"NCT03849287","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-02-25","conditions":"Hypertension, Dyslipidemias","enrollment":36},{"nctId":"NCT03659149","phase":"PHASE1","title":"Pharmacokinetics and Safety Profile of CKD-333","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-08","conditions":"Hypertension, Dyslipidemias","enrollment":37},{"nctId":"NCT03017950","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction of CKD-330 and D086","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-12","conditions":"Hypertension, Hyperlipidemias","enrollment":83},{"nctId":"NCT02586311","phase":"PHASE3","title":"CKD-330 Phase 3 Trial in Amlodipine Non-responder","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-01","conditions":"Hypertension","enrollment":160},{"nctId":"NCT02811731","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04","conditions":"Hypertension","enrollment":32},{"nctId":"NCT02801526","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04","conditions":"Hypertension","enrollment":32},{"nctId":"NCT02548286","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-08","conditions":"Hypertension","enrollment":53},{"nctId":"NCT02206165","phase":"PHASE2","title":"A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-03","conditions":"Essential Hypertension","enrollment":456},{"nctId":"NCT02186496","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-07","conditions":"Hypertension","enrollment":32},{"nctId":"NCT02064621","phase":"PHASE1","title":"CKD-330 Drug-Drug Interaction Study (Candesartan)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-06","conditions":"Hypertension","enrollment":24},{"nctId":"NCT02064556","phase":"PHASE1","title":"CKD-330 Drug-Drug Interaction Study (Amlodipine)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-05","conditions":"Hypertension","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKD-330","genericName":"CKD-330","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}